An experimental Alzheimer’s drug has been shown to slow significantly the cognitive and functional decline linked to the disease in results hailed as “remarkable” by experts, despite some patients experiencing serious side effects.
United States pharmaceutical giant Eli Lilly announced on Wednesday that in a late-stage trial of nearly 1,200 people in the early stages of Alzheimer’s disease, the drug, donanemab, slowed the progression of symptoms by 35 percent over a period of 18 months compared with a placebo.
